{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:26:58Z","timestamp":1772278018721,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.clinthera.2008.10.011","type":"journal-article","created":{"date-parts":[[2008,11,18]],"date-time":"2008-11-18T06:26:59Z","timestamp":1226989619000},"page":"1766-1781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study"],"prefix":"10.1016","volume":"30","clinical-trial-number":[{"clinical-trial-number":"nct00454740","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael B.","family":"Chancellor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristene","family":"Whitmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Kobashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Siami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mickey","family":"Karram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Laram\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"James P.","family":"Capo'","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raafat","family":"Seifeldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Forero-Schwanhaeuser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrani","family":"Nandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.10.011_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: Report from the Standardisation Sub-Committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.10.011_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1464-410X.2005.05654.x","article-title":"Health-related consequences of overactive bladder: An economic perspective","volume":"96","author":"Hu","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2008.10.011_bib3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1464-410X.2005.05889.x","article-title":"Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries","volume":"97","author":"Irwin","year":"2006","journal-title":"BJU Int."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2008.10.011_bib4","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.maturitas.2005.09.005","article-title":"Patient-reported impact of urinary incontinence\u2014results from treatment seeking women in 14 European countries","volume":"52","author":"Monz","year":"2005","journal-title":"Maturitas."},{"issue":"Suppl 11","key":"10.1016\/j.clinthera.2008.10.011_bib5","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2008.10.011_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","article-title":"The impact of urinary urgency and frequency on healthrelated quality of life in overactive bladder: Results from a national community survey","volume":"7","author":"Coyne","year":"2004","journal-title":"Value Health."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2008.10.011_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2006.05.045","article-title":"Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatment","volume":"68","author":"Brubaker","year":"2006","journal-title":"Urology."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.10.011_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2004.10.037","article-title":"The patient's perspective: Redefining end points","volume":"64","author":"Palmtag","year":"2004","journal-title":"Urology."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2008.10.011_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2006.05.044","article-title":"Assessment of treatment outcomes in patients with overactive bladder: Importance of objective and subjective measures","volume":"68","author":"Abrams","year":"2006","journal-title":"Urology."},{"key":"10.1016\/j.clinthera.2008.10.011_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1520-6777(1998)17:3<249::AID-NAU9>3.0.CO;2-D","article-title":"Standardization of outcome studies in patients with lower urinary tract dysfunction: A report on general principles from the Standardisation Committee of the International Continence Society","volume":"17","author":"Mattiasson","year":"1998","journal-title":"Neurourol Urodyn."},{"key":"10.1016\/j.clinthera.2008.10.011_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1185\/030079902125000570","article-title":"Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET)","volume":"18","author":"Sussman","year":"2002","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2008.10.011_bib12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.clinthera.2006.11.010","article-title":"Symptom bother and healthrelated quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare Open-Label Trial (VOLT)","volume":"28","author":"Garely","year":"2006","journal-title":"Clin Ther."},{"issue":"Suppl 5A","key":"10.1016\/j.clinthera.2008.10.011_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(99)00492-6","article-title":"Muscarinic receptor antagonists in the treatment of overactive bladder","volume":"55","author":"Chapple","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2008.10.011_bib14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol."},{"key":"10.1016\/j.clinthera.2008.10.011_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder","volume":"10","author":"Drutz","year":"1999","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct."},{"key":"10.1016\/j.clinthera.2008.10.011_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extendedrelease oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT Study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.clinthera.2008.10.011_bib17","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","article-title":"Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized controlled trial","volume":"165","author":"Malone-Lee","year":"2001","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2008.10.011_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology."},{"key":"10.1016\/j.clinthera.2008.10.011_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, doubleblind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.clinthera.2008.10.011_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1046\/j.1464-410X.2003.04085.x","article-title":"The use of tolterodine in children after oxybutynin failure","volume":"91","author":"Bolduc","year":"2003","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2008.10.011_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.urology.2004.09.036","article-title":"Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?","volume":"65","author":"Yucel","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2008.10.011_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(05)66095-8","article-title":"A short-term, multicenter, randomized doubleblind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence","volume":"166","author":"Davila","year":"2001","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2008.10.011_bib23","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2008.10.011_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","article-title":"Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2008.10.011_bib25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2008.10.011_bib26","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1185\/03007990802081766","article-title":"Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER","volume":"24","author":"Zinner","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2008.10.011_bib27_1","unstructured":"Guideline for good clinical practice. ICH Harmonised Tripartite Guideline [EMEA Web site]."},{"key":"10.1016\/j.clinthera.2008.10.011_bib28_1","unstructured":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects [WMA Web site]."},{"key":"10.1016\/j.clinthera.2008.10.011_bib29","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","article-title":"The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder","volume":"49","author":"Coyne","year":"2006","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2008.10.011_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/nau.20110","article-title":"Test-retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ)","volume":"24","author":"Matza","year":"2005","journal-title":"Neurourol Urodyn."},{"key":"10.1016\/j.clinthera.2008.10.011_bib31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and healthrelated quality of life questionnaire: The OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2008.10.011_bib32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2006.03.088","article-title":"Determining the importance of change in the overactive bladder questionnaire","volume":"176","author":"Coyne","year":"2006","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2008.10.011_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1742-1241.2006.01067.x","article-title":"Solifenacin significantly improves all symptoms of overactive bladder syndrome","volume":"60","author":"Chapple","year":"2006","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.clinthera.2008.10.011_bib34","series-title":"Practical Statistics for Medical Research","year":"1991"},{"key":"10.1016\/j.clinthera.2008.10.011_bib35","series-title":"Tolterodine tartrate [package insert]","year":"2008"},{"key":"10.1016\/j.clinthera.2008.10.011_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/nau.20342","article-title":"The responsiveness of the OAB-q among OAB patient subgroups","volume":"26","author":"Coyne","year":"2007","journal-title":"Neurourol Urodyn."},{"key":"10.1016\/j.clinthera.2008.10.011_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1464-410X.2004.05255.x","article-title":"Improved quality of life in patients with overactive bladder symptoms treated with solifenacin","volume":"95","author":"Kelleher","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2008.10.011_bib38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2008.10.011_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1464-410X.2007.06517.x","article-title":"Redefining response in overactive bladder syndrome","volume":"99","author":"Payne","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2008.10.011_bib40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double-blind placebo and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.10.011_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1464-410X.2005.05651.x","article-title":"Role of muscarinic receptor antagonists in urgency and nocturia","volume":"96","author":"Michel","year":"2005","journal-title":"BJU Int."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808003329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808003329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:47:58Z","timestamp":1758962878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808003329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0149291808003329"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.10.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}